Phase 1 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender
• People who have already been through at least 3 previous treatment plans for their cancer, including treatments from two specific drug groups: proteasome inhibitors and immunomodulatory agents
• People whose multiple myeloma or plasma cell leukaemia has come back, gotten worse, or stopped responding to treatment
• People whose cancer cells show a specific protein marker called GPRC5D, confirmed by a lab test on tissue such as a bone marrow sample
• People whose disease can be measured through at least one of the following: a bone marrow sample showing enough abnormal cells, a blood or urine protein test above certain levels, or a specific light chain blood test result — or, for disease outside the bone marrow, a detectable lesion of at least 2 cm in size
• People with a general health and activity level rated 0, 1, or 2 on a standard medical scale (meaning able to carry out some or all daily activities, with or without limitations) (confirm with trial site)
• People with a life expectancy of at least 12 weeks
• People whose blood counts, liver, kidneys, clotting, oxygen levels, and heart function all meet specific minimum levels set by the trial
• People (and their partners) who agree to use effective contraception from the time of consent until one year after the treatment infusion
• People who are able to sign the consent form in person before any screening begins

Who may not be able to join:

• People who have a condition called graft-versus-host disease (GVHD), or who need long-term medication to suppress their immune system
• People who have received certain cancer treatments too recently before the blood collection procedure — including some antibody therapies, chemotherapy, or other anti-cancer drugs within specific timeframes set by the trial
• People who have taken higher-dose steroid tablets (above a set threshold) within 7 days before screening, unless used for breathing or applied to the skin
• People with high blood pressure that cannot be controlled with medication
• People with serious heart conditions, including unstable chest pain, a heart attack within the past 6 months, significant heart failure, or severe irregular heartbeat
• People with unstable ongoing illnesses affecting the liver, kidneys, or metabolism that require medical management
• People who have had a different cancer in the past 5 years, with some exceptions for certain successfully treated cancers (such as specific skin cancers, early-stage cervical cancer, localised prostate cancer, or early breast cancer after surgery)
• People who have previously had an organ transplant
• People who have had major surgery within 2 weeks before the blood collection procedure, or who are planning surgery during or shortly after the study treatment
• People who have taken part in another interventional clinical trial within 1 month before signing the consent form
• People with an active uncontrolled infection requiring treatment by tablet or injection within 7 days before the blood collection procedure (with some minor exceptions)
• People who test positive for hepatitis B, hepatitis C, HIV, cytomegalovirus (CMV), or syphilis under specific testing conditions
• People who are pregnant or breastfeeding
• People with a mental health condition, a disorder affecting consciousness, or a disease of the brain or nervous system
• People whom the research team considers unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.